Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 7/20 | 0.71 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.71 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 3/20 | 0.66 |
| ▸ | HPGD | P15428 | 1/20 | 0.66 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933481 | 0.90 | HDAC1 (0.63) | KCNK3KCNK9RAB9ANPC1HPGD | |
| SCHEMBL26287842 | 0.87 | NR1H4 (0.69) | KCNK3KCNK9RAB9ANPC1MEN1 | |
| SCHEMBL3783926 | 0.86 | KCNK3 (0.65) | KCNK3KCNK9RAB9ANPC1HPGD | |
| SCHEMBL2298254 | 0.84 | KCNK3 (1.00) | KCNK3KCNK9RAB9ANPC1HPGD | |
| SCHEMBL3786011 | 0.83 | NPC1 (0.74) | KCNK3KCNK9RAB9ANPC1MEN1 | |
| SCHEMBL26819992 | 0.83 | DEGS1 (0.57) | KCNK3KCNK9RAB9ANPC1MEN1 | |
| SCHEMBL4072382 | 0.83 | TP53 (0.61) | RAB9ANPC1SIRT1MEN1KMT2A | |
| SCHEMBL2555750 | 0.83 | NPC1 (0.69) | KCNK3KCNK9RAB9ANPC1HPGD | |
| SCHEMBL2564353 | 0.82 | TRPV1 (0.52) | KCNK3KCNK9NLRP3TRPV1ALDH1A1 | |
| SCHEMBL3976625 | 0.81 | MAPT (0.72) | KCNK3KCNK9RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| US-20090306107-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| US-20090306107-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-6919382-B2 | Preparation and uses of conjugated solid supports for boronic acids | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2005-07-19 | — | — | US | disclosed |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | GOVERNORS OF THE UNIVERSITY OF ALBERTA, THE (CA) | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | KCNK3 2193/4885KCNK9 2467/4885RAB9A 1357/4885 |
| US-20030044840-A1 | Preparation and uses of conjugated solid supports for boronic acids | SLC43A1, SBDS, SLC7A5 | KCNK3 4370/4885KCNK9 4479/4885RAB9A 2477/4885 |
| US-20090306107-A1 | Organic Compounds | BRAF, MAP3K1, RAF1 | KCNK3 1776/4885KCNK9 2622/4885RAB9A 4015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.